共 12 条
- [11] QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy-Results from the TASCO1 phase II study. [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
- [12] Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting [J]. BREAST CARE, 2024, 19 (01) : 49 - 61